- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.39 Form of Restricted Stock Grant Agreement
- 10.40 Form of Non-qualified Stock Option Grant Agreement
- 10.41 Form of Incentive Stock Option Grant Agreement
- 21.1 Subsidiary of Pro Pharmaceuticals, Inc.
- 23.1 Consent of Deloitte & Touche LLP
- 23.2 Consent of Vitale, Caturano & Company, PC
- 31.1 Certification of CEO Pursuant to Section 302
- 31.2 Certification of CFO Pursuant to Section 302
- 32.1 Certification of CEO Pursuant to Section 906
- 32.2 Certification of CFO Pursuant to Section 906
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
As independent registered public accountants, we hereby consent to the incorporation of our report dated March 30, 2009 (which report expresses an unqualified opinion and contains explanatory paragraphs relating to substantial doubt with respect to the Company’s ability to continue as a going concern and relating to the Company’s adoption of Statement of Financial Accounting Standards (“SFAS”) No. 157, “Fair Value Measurements” effective January 1, 2008) relating to the consolidated financial statements of Pro-Pharmaceuticals, Inc. for the year ended December 31, 2008, included in this Form 10-K, into the Company’s previously filed Registration Statements on Form S-3 (File Nos. 333-109887, 333-115118, 333-118907, 333-111650, 333-132459, 333-148911 and 333-150898) and on Form S-8 (File Nos. 333-116629 and 333-109893).
/s/ Vitale, Caturano & Company, P.C.
Boston, Massachusetts
March 30, 2009